BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica’s experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. Water Street merged BioClinica and CCBR-SYNARC in 2014 to transform the company into a leading provider of specialty outsourced clinical services.
John Hubbard, Ph.D., FCP
President & Chief Executive OfficerWork with us
John Hubbard is a leader in the clinical services and biopharmaceutical R&D industries, with over three decades of experience including executive-level positions at Pfizer, ICON, Parexel and Hoechst Marion Roussel Pharmaceuticals. Prior to joining BioClinica, he was senior vice president and worldwide head of development operations for Pfizer, where he directed and oversaw clinical trial operations and management of more than 450 clinical projects. John was also a founding member of the board of directors of Transcelerate Biopharma, Inc. Previously, he was group president, Clinical Research Services at ICON Clinical Research. He is also a board member of Agile Therapeutics and the Association of Clinical Research Organizations (ACRO), and an advisory board member and fundraising vice-chair for the Children’s Brain Tumor Foundation. John received a bachelor’s degree in biopsychology from the University of Santa Clara and a doctorate from the University of Tennessee. He was an NIH postdoctoral fellow in Cardiovascular and Clinical Pharmacology at the University of Texas Health Sciences Center. John is an active member of the Society of Clinical Pharmacology and Therapeutics, a board certified diplomate in Applied Pharmacology and was elected as a Fellow of the American College of Clinical Pharmacology.